Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study

Figures

• 

  Fig. 1. Trial profile (reprinted with permission from Kakihana et al. Lancet Respiratory Medicine 2020;8:863–872). *Multiple reasons may apply. †One patient assigned to the control group was incorrectly given landiolol. This patient was included in the control group for the efficacy analysis and in the landiolol group for the safety analysis. ‡One patient assigned to the landiolol group did not meet the inclusion criteria but was administered landiolol. This patient was excluded from the efficacy analysis but was included in the safety analysis.

• 

  Fig. 2. Subgroup analysis of the percentage of patients whose heart rate (HR) was adjusted to 60–94 beats/min at 24 h after randomisation. The size of the markers represents the number of patients included in the subgroup. Results of the multivariate analysis with adjustment for age and HR at baseline are shown in Fig. S1. APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval; eGFR = estimated glomerular filtration rate; SOFA = Sequential Organ Failure Assessment.

• 

  Fig. 3. Subgroup analysis of the percentage of patients who developed new arrhythmias by 168 h after randomisation. The size of the markers represents the number of patients included in the subgroup. Hazard ratios are plotted on a log-scale. Results of the multivariate analysis with adjustment for age and heart rate at baseline are shown in Fig. S2. APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval; eGFR = estimated glomerular filtration rate; NC = upper limit not calculable; SOFA = Sequential Organ Failure Assessment.

• 

  Fig. 4. Subgroup analysis of mortality by 28 days after randomisation. The size of the markers represents the number of patients included in the subgroup. Hazard ratios are plotted on a log-scale. Results of the multivariate analysis with adjustment for age and heart rate at baseline are shown in Fig. S3. APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval; eGFR = estimated glomerular filtration rate; NC = upper limit not calculable; SOFA = Sequential Organ Failure Assessment.

• 

  Fig. 5. Subgroup analysis of overall adverse events. The size of the markers represents the number of patients included in the subgroup. Results of the multivariate analysis with adjustment for age and heart rate at baseline are shown in Fig. S4. APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; beats/min = beats per minute; CI = confidence interval; eGFR = estimated glomerular filtration rate; SOFA = Sequential Organ Failure Assessment.